What is Sequence?
Sequence (formerly Stepful) is a telehealth weight management program focused on insurance-covered GLP-1 prescriptions. Their core value proposition: they help you get brand-name GLP-1 medications (Wegovy, Zepbound) covered by your insurance, with obesity medicine specialists managing your care.
This insurance-first approach distinguishes Sequence from the self-pay compounded programs (Hims, Mochi) and positions it alongside Calibrate as a premium, clinically-intensive option — but with a different pricing model.
How it works
Insurance check first. Before you pay anything, Sequence verifies whether your insurance covers GLP-1 medications. This pre-screening avoids the frustration of going through a clinical consultation only to discover your payer won't cover the drug.
Provider match. You're paired with a board-certified obesity medicine physician or a provider with significant obesity medicine experience. Visits are via video.
Prior authorization. Sequence's team handles the prior authorization process — the paperwork required to get your insurer to approve coverage. This is a significant value-add. Prior auth for GLP-1s is often denied on first attempt, and Sequence's team knows how to appeal effectively.
Ongoing management. Regular video visits for dose titration, side effect management, and metabolic monitoring. Frequency varies by phase — typically monthly during titration, quarterly during maintenance.
Pricing
Sequence's model is designed to minimize out-of-pocket costs by leveraging insurance:
Program fee: Approximately $99/month. This covers all provider consultations, prior authorization support, and program access.
Medication: Billed through your insurance. If your plan covers Wegovy or Zepbound, you pay your standard specialty medication copay (typically $25–$75/month with good coverage, but varies widely by plan).
Total cost with insurance: Often $125–$175/month all-in (program fee + medication copay). This is dramatically less than the $500–$1,500/month total for self-pay compounded programs.
Without insurance coverage: Sequence is less useful. If your insurer denies coverage even after appeals, you're paying the program fee plus full brand-name drug cost ($1,000+/month), which is worse economics than going directly to a compounded provider.
Clinical approach
Provider quality. Consistently strong. Sequence's emphasis on obesity medicine specialists means you're getting providers who understand GLP-1 pharmacology deeply and can manage complex titration scenarios, side effects, and comorbidity interactions.
Brand-name focus. Sequence works almost exclusively with FDA-approved brand-name GLP-1s. This means your medication is the exact formulation studied in the STEP and SURMOUNT trials, manufactured under full FDA oversight with consistent potency and purity.
Lab-informed care. Metabolic labs are part of the protocol. Your provider tracks A1c, lipid panels, and other markers to assess the metabolic benefits beyond weight loss.
No compounded option. If you specifically want compounded semaglutide or tirzepatide, Sequence isn't the program for you. They don't offer compounded formulations.
Pros
Insurance optimization. Sequence's prior auth team is their most valuable asset. They handle the back-and-forth with insurers that most patients find overwhelming.
Cost-effective with coverage. If your insurance covers a GLP-1, the total monthly cost through Sequence is hard to beat.
Provider quality. Obesity medicine specialists, not general practitioners prescribing GLP-1s as a side business.
Brand-name medications. FDA-approved drugs with established safety and efficacy data.
Cons
Insurance-dependent. The entire value proposition relies on insurance coverage. If your plan doesn't cover GLP-1s for obesity, Sequence's advantages evaporate.
No compounded alternative. If insurance denies coverage, Sequence can't pivot to a compounded formulation like Ro or Found can.
Less coaching structure. Sequence focuses on clinical management rather than behavior change. If you want a Calibrate-style coaching curriculum, you won't find it here.
Limited medication breadth. Sequence focuses on GLP-1s. If you need combination therapy (metformin, Contrave, etc.), a program like Found offers more options.
Sequence vs. Calibrate
Both target insured patients wanting brand-name GLP-1s, but they differ:
Calibrate charges more ($1,500+ annually) but includes a year-long structured behavior change curriculum with dedicated coaching. It's a comprehensive metabolic reset program with medication as one component.
Sequence charges less ($99/month, ~$1,200 annually) and focuses on clinical management — great providers, excellent insurance navigation, but less behavior change support.
Choose Calibrate if you want the full program experience. Choose Sequence if you have strong insurance coverage and want excellent clinical management at a lower price point.
Who is Sequence best for?
Sequence is best for patients who:
- Have employer or marketplace insurance that covers GLP-1
medications (or might cover them with prior authorization)
- Want brand-name medications managed by obesity medicine
specialists
- Are comfortable self-directing their nutrition and exercise
(don't need intensive coaching)
- Want to minimize total monthly cost through insurance
Sequence is not ideal if you:
- Don't have insurance or have a plan that excludes weight
management drugs
- Want compounded medications
- Need structured coaching and accountability
- Want access to non-GLP-1 weight management drugs
Our bottom line
Sequence is the best option for a specific but large audience: insured patients who want brand-name GLP-1s managed by real obesity medicine specialists at the lowest possible cost. The prior authorization expertise alone can save months of frustration and thousands of dollars.
If that describes you, Sequence is a strong pick. If you don't have GLP-1-friendly insurance, look at programs with more flexible medication options (Found, Ro) or self-pay compounded programs (Hims, Mochi) where insurance isn't part of the equation.